10jili official website Lawmakers impeach presidentMike Wolfe's generous donation amid American Pickers co-star Danielle Colby's health battleUS homelessness up 18% as affordable housing remains out of reach for many people Federal officials say the United States saw an 18.1% increase in homelessness, a dramatic rise driven mostly by a lack of affordable housing as well as devastating natural disasters and a surge of migrants in several parts of the country. The U.S. Department of Housing and Urban Development said that federally required tallies taken across the country in January found that more than 770,000 people were counted as homeless. That increase comes on top of a 12% increase in 2023, which HUD blamed on soaring rents and the end of pandemic assistance. Among the most concerning trends was a nearly 40% rise in family homelessness. An online debate over foreign workers in tech shows tensions in Trump's political coalition WEST PALM BEACH, Fla. (AP) — An online spat between factions of Donald Trump’s supporters over immigration and the tech industry has thrown internal divisions in the president-elect’s political movement into public display. The argument previews fissures and contradictory views his coalition could bring to the White House. The rift laid bare tensions between the newest flank of Trump’s movement — that is, wealthy members of the tech world who want more highly skilled workers in their industry — and people in Trump’s Make America Great Again base who championed his hardline immigration policies. A 9th telecoms firm has been hit by a massive Chinese espionage campaign, the White House says WASHINGTON (AP) — A top White House official says a ninth U.S. telecoms firm has been confirmed to have been hacked as part of a sprawling Chinese espionage campaign that gave officials in Beijing access to private texts and phone conversations of an unknown number of Americans. Administration officials said this month that at least eight telecommunications companies, as well as dozens of nations, had been affected by the Chinese hacking blitz known as Salt Typhoon. But Anne Neuberger, a deputy national security adviser, said Friday that a ninth victim had been identified after the administration released guidance to companies about how to hunt for Chinese culprits in their networks. Israeli troops burn northern Gaza hospital after forcibly removing staff and patients, officials say DEIR AL-BALAH, Gaza Strip (AP) — Gaza's Health Ministry says Israeli troops have stormed one of the last hospitals operating in the territory's north on Friday and forced many of the staff and patients outside. Then they had to remove their clothes in winter weather. It was the latest assault on Kamal Adwan Hospital. Parts of it were set on fire. Staff say it has been hit multiple times in the past three months by Israeli troops waging an offensive against Hamas fighters in surrounding neighborhoods. Israel's military says Hamas uses the hospital as a base. It did not provide evidence, and hospital officials have denied it. Azerbaijani and U.S. officials suggest plane that crashed may have been hit by weapons fire U.S. and Azerbaijani officials have said weapons fire may have brought down an Azerbaijani airliner that crashed on Wednesday, killing 38 people. The statements from Rashad Nabiyev and White House national security spokesman John Kirby on Friday raised pressure on Russia. Officials in Moscow have said a drone attack was underway in the region that the Azerbaijan Airlines flight was destined for but have not addressed statements from aviation experts who blamed the crash on Russian air defenses responding to a Ukrainian attack. The plane was flying from Azerbaijan’s capital of Baku to Chechnya on Wednesday when it crashed, killing 38 people and leaving all 29 survivors injured. Court rules Georgia lawmakers can subpoena Fani Willis for information related to her Trump case ATLANTA (AP) — A judge has ruled that the Georgia state Senate can subpoena Fulton County District Attorney Fani Willis. It's part of a inquiry into whether Willis has engaged in misconduct during her prosecution of President-elect Donald Trump. But Fulton County Superior Court Judge Shukura Ingram is giving Willis the chance to contest whether lawmakers’ demands are overly broad before Willis responds. A Republican-led committee was formed earlier this year and sent subpoenas to Willis in August seeking to compel her to testify during its September meeting and to produce scores of documents. Willis argued that the committee didn’t have the power to subpoena her. In states that ban abortion, social safety net programs often fail families MEMPHIS, Tenn. (AP) — Tennessee has a nearly total abortion ban and a porous safety net for mothers and young children. GOP state leaders in Tennessee and other states that banned abortion after the U.S. Supreme Court overturned Roe v. Wade in 2022 argue that they are bolstering services for families. Recent research and an analysis by The Associated Press has found that from the time a Tennessee woman gets pregnant, she faces greater obstacles to a healthy pregnancy, a healthy child and a financially stable family life than the average American mom. Maryland sues maker of Gore-Tex over pollution from toxic 'forever chemicals' Maryland is suing the company that produces the waterproof material Gore-Tex. State officials say the company's leaders kept using so-called “forever chemicals” long after learning about serious health risks. The federal complaint alleges Delaware-based W.L. Gore & Associates polluted the air and water around 13 facilities in northeastern Maryland with chemicals that have been linked to certain cancers, reproductive issues and high cholesterol. They’re nearly indestructible and can build up in various environments, including the human body. The company stopped using the harmful chemicals in 2014 and says it’s working with state regulators on testing and cleanup efforts. Man indicted in burning death of woman inside a New York City subway train, prosecutors say NEW YORK (AP) — The man accused of burning a woman to death inside a New York City subway train has been indicted on state charges. A prosecutor announced Sebastian Zapeta’s indictment at a court hearing Friday. The development comes days after Zapeta’s arrest and subsequent police questioning in which they say he identified himself in photos and surveillance video showing the fire being lit. The indictment will be under seal until Jan. 7. He remains jailed. Federal immigration officials say the 33-year-old Zapeta is from Guatemala and entered the U.S. illegally. Authorities are continuing to work to identify the victim. Alex Ovechkin is on track to break Wayne Gretzky's NHL career goals record Alex Ovechkin of the Washington Capitals is chasing the NHL career goals record of 894 held by Wayne Gretzky. Ovechkin entered the season 42 goals short of breaking a record that long seemed unapproachable. He is set to play again Saturday at the Toronto Maple Leafs after missing more than a month with a broken left fibula. Ovechkin was on pace to get to 895 sometime in February before getting injured. At 868, he his 27 goals away from passing Gretzky.

Mobile phones turned 40 in 2024, but there’s no need for a foldables or AR glasses fueled midlife crisis before they're 50

Feds suspend ACA marketplace access to companies accused of falsely promising ‘cash cards’DEIR AL-BALAH, Gaza Strip (AP) — Israeli troops stormed one of the last hospitals operating in northern Gaza on Friday, forcing many staff and patients outside to strip in winter weather , the territory’s health ministry said. The army denied claims it had entered or set fire to the complex and accused Hamas of using the facility for cover. Kamal Adwan Hospital has been hit multiple times over the past three months by Israeli troops waging an offensive against Hamas fighters in surrounding neighborhoods, according to staff. The ministry said a strike on the hospital a day earlier killed five medical staff. Israel's military said it was conducting operations against Hamas infrastructure and militants in the area and had ordered people out of the hospital, but said it had not entered the complex as of Friday night. It repeated claims that Hamas militants operate inside Kamal Adwan but provided no evidence. Hospital officials have denied that. The Health Ministry said troops forced medical personnel and patients to assemble in the yard and remove their clothes. Some were led to an unknown location, while some patients were sent to the nearby Indonesian Hospital, which was knocked out of operation after an Israel raid this week. Israeli troops during raids frequently carry out mass detentions, stripping men to their underwear for questioning in what the military says is a security measure as they search for Hamas fighters. The Associated Press doesn’t have access to Kamal Adwan, but armed plainclothes members of the Hamas-led police forces have been seen in other hospitals, maintaining security but also controlling access to parts of the facilities. The Health Ministry said Israeli troops also set fires in several parts of Kamal Adwan, including the lab and surgery department. It said 25 patients and 60 health workers remained in the hospital. The account could not be independently confirmed, and attempts to reach hospital staff were unsuccessful. “Fire is ablaze everywhere in the hospital,” an unidentified staff member said in an audio message posted on social media accounts of hospital director Hossam Abu Safiya. The staffer said some evacuated patients had been unhooked from oxygen. “There are currently patients who could die at any moment,” she said. Lt. Col. Nadav Shoshani, an Israeli military spokesman, denied the accusations. “While IDF troops were not in the hospital, a small fire broke out in an empty building inside the hospital that is under control,” he said Friday night. He said a preliminary investigation found “no connection” between military activity and the fire. The Israeli military heavily restricts the movements of Palestinians in Gaza and has barred foreign journalists from entering the territory throughout the war, making it difficult to verify information. “These actions put the lives of all of these people in even more danger than what they faced before,” U.N. spokesperson Stephanie Tremblay told journalists, and noted colleagues' reports of “significant damage” to the hospital. It should be protected as international law requires, she added. Since October, Israel’s offensive has virtually sealed off the northern Gaza areas of Jabaliya, Beit Hanoun and Beit Lahiya and leveled large parts of them. Tens of thousands of Palestinians were forced out but thousands are believed to remain in the area, where Kamal Adwan and two other hospitals are located. Troops raided Kamal Adwan in October, and on Tuesday troops stormed and evacuated the Indonesian Hospital. The area has been cut off from food and other aid for months , raising fears of famine . The United Nations says Israeli troops allowed just four humanitarian deliveries to the area from Dec. 1 to Dec. 23. The Israeli rights group Physicians for Human Rights-Israel this week petitioned Israel’s High Court of Justice, seeking a halt to military attacks on Kamal Adwan. It warned that forcibly evacuating the hospital would “abandon thousands of residents in northern Gaza.” Before the latest deaths Thursday, the group documented five other staffers killed by Israeli fire since October. Israel launched its campaign in Gaza vowing to destroy Hamas after the group’s Oct. 7, 2023, attack on southern Israel in which militants killed around 1,200 people and abducted some 250 others. Around 100 Israelis remain captive in Gaza, around a third believed to be dead. Israel’s nearly 15-month-old campaign of bombardment and offensives has devastated the territory’s health sector. A year ago, it carried out raids on hospitals in northern Gaza, including Kamal Adwan, Indonesian and al-Awda Hospital, saying they served as bases for Hamas, though it presented little evidence. Israel’s campaign has killed more than 45,400 Palestinians, more than half women and children, and wounded more than 108,000 others, according to the Health Ministry. Its count does not distinguish between civilians and combatants. More than 90% of Gaza’s 2.3 million Palestinians have been driven from their homes, most now sheltering in sprawling tent camps in south and central Gaza. Children and adults, many barefoot, huddled Friday on the cold sand in tents whose plastic and cloth sheets whipped in the wind. Overnight temperatures can dip into the 40s Fahrenheit (below 10 Celsius), and sea spray from the Mediterranean can dampen tents just steps away. "I swear to God, their mother and I cover ourselves with one blanket and we cover (their five children) with three blankets that we got from neighbors. Sea waters drowned everything that was ours,” said Muhammad al-Sous, displaced from Beit Lahiya in the north. The children collect plastic bottles to make fires, and pile under the blankets when their only set of clothes is washed and dried in the wind. At least three babies in Gaza have died from exposure to cold in recent days , doctors there have said, and the Health Ministry said an adult — a nurse who worked at the European Hospital — also died this week. Khaled and Keath reported from Cairo. Associated Press writer Edith M. Lederer at the United Narions contributed to this report.

Fines for express lane weaving to start with the new yearNone

Barclays PLC increased its position in shares of First Mid Bancshares, Inc. ( NASDAQ:FMBH – Free Report ) by 327.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,347 shares of the bank’s stock after buying an additional 26,315 shares during the quarter. Barclays PLC owned 0.14% of First Mid Bancshares worth $1,337,000 at the end of the most recent quarter. Several other institutional investors and hedge funds have also recently added to or reduced their stakes in FMBH. Dimensional Fund Advisors LP increased its holdings in First Mid Bancshares by 5.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 778,135 shares of the bank’s stock valued at $25,584,000 after buying an additional 36,769 shares during the period. Wellington Management Group LLP increased its stake in First Mid Bancshares by 7.3% in the third quarter. Wellington Management Group LLP now owns 387,926 shares of the bank’s stock valued at $15,094,000 after acquiring an additional 26,560 shares during the period. American Century Companies Inc. raised its position in First Mid Bancshares by 23.7% in the second quarter. American Century Companies Inc. now owns 340,343 shares of the bank’s stock worth $11,190,000 after purchasing an additional 65,314 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in First Mid Bancshares by 7.1% during the second quarter. Bank of New York Mellon Corp now owns 118,048 shares of the bank’s stock worth $3,881,000 after purchasing an additional 7,849 shares during the period. Finally, Creative Planning boosted its holdings in First Mid Bancshares by 2.1% during the second quarter. Creative Planning now owns 106,397 shares of the bank’s stock valued at $3,498,000 after purchasing an additional 2,186 shares in the last quarter. 47.57% of the stock is currently owned by institutional investors. First Mid Bancshares Stock Down 1.8 % First Mid Bancshares stock opened at $36.99 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41. The company has a fifty day simple moving average of $40.34 and a 200 day simple moving average of $38.07. The company has a market cap of $884.50 million, a P/E ratio of 11.38 and a beta of 0.91. First Mid Bancshares, Inc. has a 1-year low of $28.86 and a 1-year high of $43.86. First Mid Bancshares Dividend Announcement Analyst Ratings Changes Several equities analysts recently issued reports on the stock. Piper Sandler lifted their price target on shares of First Mid Bancshares from $46.00 to $47.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Keefe, Bruyette & Woods increased their price target on First Mid Bancshares from $42.00 to $45.00 and gave the stock a “market perform” rating in a research report on Wednesday, December 4th. Stephens cut First Mid Bancshares from an “overweight” rating to an “equal weight” rating in a report on Monday, December 9th. Finally, DA Davidson lowered First Mid Bancshares from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $44.00 to $47.00 in a research note on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.50. Get Our Latest Stock Analysis on First Mid Bancshares First Mid Bancshares Profile ( Free Report ) First Mid Bancshares, Inc, a financial holding company, provides community banking products and services to commercial, retail, and agricultural customers in the United States. It accepts various deposit products, such as demand deposits, savings accounts, money market deposits, and time deposits. The company’s loan products include commercial real estate, commercial and industrial, agricultural and agricultural real estate, residential real estate, and consumer loans, as well as construction and land development, 1-4 family residential properties, and multifamily residential properties loans; and other loans comprising loans to municipalities to support community projects, such as infrastructure improvements or equipment purchases. Featured Articles Five stocks we like better than First Mid Bancshares How Investors Can Identify and Successfully Trade Gap-Down Stocks Buffett Takes the Bait; Berkshire Buys More Oxy in December Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index Top 3 ETFs to Hedge Against Inflation in 2025 Investing in Construction Stocks These 3 Chip Stock Kings Are Still Buys for 2025 Receive News & Ratings for First Mid Bancshares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Mid Bancshares and related companies with MarketBeat.com's FREE daily email newsletter .

Western Digital's SVP Gene Zamiska sells $24,240 in stockA Barbadian scientist has been honoured among the Hemisphere’s brightest minds by the Organisation of American States (OAS). Dr Cardinal Warde was the lone Caribbean scientist among seven distinguished individuals from the Americas, awarded the prestigious Science, Technology and Innovation Award of the Americas during the VII Meeting of Ministers and High-Level Authorities of Science and Technology, (REMYCT). The ceremony celebrated trailblazers from Barbados, Canada, Chile, Honduras, Mexico, Uruguay and the United States for their exceptional contributions to science and technology, as well as their commitment to fostering cooperation and development across OAS member states. The other awardees were Dr Alejandro Adem of Canada, president of the Natural Sciences and Engineering Research Council of Canada (NSERC); Dr Pablo Zamora of Chile, president of Fundación Chile; Dr Rosibel Ochoa of Honduras, Associate Vice Chancellor at UC Riverside; Dr Arturo Reyes Sandoval of Mexico, director of the National Polytechnic Institute (IPN); Dr Natacha DePaola of the United States, professor of biomedical engineering at the Illinois Institute of Technology (IIT), and director of the Illinois Tech Digital Medical Engineering and Technology Research and Education Centre and Dr Henry Cohen of Uruguay, head of the Department of Gastroenterology at the Hospital of the University of the Republic, and director of the ECHO Project. In her congratulatory message, OAS executive secretary for integral development, Kim Osborne, spoke of the importance of ensuring the contributions from the Americas to global science and innovation does not go unnoticed. “Each of you in your own way have made your mark on the world of science, technology, and innovation, today the OAS simply wants to say thank you for enriching our work with your time and expertise,” she said. A Champion for Caribbean Science Dr Warde, 79, a professor of electrical engineering at the Massachusetts Institute of Technology (MIT), was recognised for his groundbreaking work in optoelectronics and his leadership in advancing science education in the Caribbean. As president of the Caribbean Diaspora for Science, Technology, and Innovation (CADSTI) and Interim Executive Director of the Caribbean Science Foundation, Dr Warde has dedicated his career to equipping the next generation of scientists and engineers with tools for success. Born in Christ Church, Warde showed an early passion for science, converting his father’s carpentry shop into a makeshift chemistry lab. After excelling at Harrison College, he pursued higher education in the United States, earning his doctorate in physics from Yale University in 1974. Pioneering Research and Innovations At MIT, where he has served since 1974, Dr Warde is a leading expert in materials and systems for optical information processing and displays. His research spans diverse fields, including optical computing, wireless communication and holography. He has developed innovative optical neural network processors and light modulators that have advanced brain-like computing and high-resolution imaging technologies. Beyond academia, Dr Warde founded multiple successful technology ventures, including Optron Systems and Radiant Images, Inc., specialising in optoelectronic systems and displays. His inventions have earned him 12 patents, underscoring his impact on the tech industry. Advocacy for Education and Development Dr Warde is equally celebrated for his contributions to education policy in the Caribbean. He has worked tirelessly as a scientific advisor to the Government of Barbados and other regional entities to enhance STEM opportunities for Caribbean youth. Through the Caribbean Science Foundation, Dr Warde oversees the Student Programme for Innovation in Science and Engineering (SPISE), a rigorous summer initiative that prepares gifted students for careers in science and engineering. He also established the Rosetta Irene Ward Memorial Scholarship Fund, supporting higher education for students from English-speaking Caribbean countries. Global Recognition Dr Warde’s accolades include the Barbados Prime Minister’s Award for Excellence and the Caribbean American Heritage Award. He is also a Fellow of The Optical Society and holds honorary doctorates from the University of the West Indies and Universidad Carlos III de Madrid. As a scientist, educator, and advocate, Dr Warde exemplifies the power of innovation and collaboration. His recognition by the OAS highlights the vital contributions of Caribbean professionals to global science and technology. The OAS Science and Technology Awards , established in 1972 as the “Bernardo Houssay” Award, honor the legacy of the esteemed Argentine Nobel laureate whose work on diabetes transformed global health. Since then, the award has celebrated outstanding achievements in fields like Biological Sciences, Physics, Chemistry, Mathematics, and Applied Technological Research. (PR) Save my name, email, and website in this browser for the next time I comment.NoneTV and Movie Merchandise Market to Grow by USD 103.5 Billion (2024-2028), Driven by E-Commerce Platform Growth, AI Redefining Market Landscape - Technavio

Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; Completed the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company which began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 ; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab; and, Met primary and secondary endpoints in the Phase 3 Pivotal Trial of Mino-Lok ® , demonstrating a statistically significant improvement in time to catheter failure of infected catheters compared to other physician-selected anti-infective lock solutions. Financial Highlights Cash and cash equivalents of $3.3 million as of September 30, 2024 ; R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 ; G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $11.8 million for the full year ended September 30, 2024 , compared to $6.6 million for the full year ended September 30, 2023 ; and, Net loss was $39.4 million , or ($5.97) per share for the full year ended September 30, 2024 compared to a net loss of $32.5 million , or ($5.57) per share for the full year ended September 30, 2023 . "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated Leonard Mazur , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Liquidity As of September 30, 2024 , the Company had $3.3 million in cash and cash equivalents. As of September 30, 2024 , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November 25, 2024 . During the year ended September 30, 2024 , the Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations. Research and Development (R&D) Expenses R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5 million during the year ended September 30, 2024 , compared to $2.0 million for the year ended September 30, 2023 , as the plan was initiated in July 2023 . For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382 , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss Net loss was $39.4 million , or ($5.97) per share for the year ended September 30, 2024 , compared to a net loss of $32.5 million , or ($5.57) per share for the year ended September 30, 2023 , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024 , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 3,251,880 $ 26,480,928 Inventory 8,268,766 — Prepaid expenses 2,700,000 7,889,506 Total Current Assets 14,220,646 34,370,434 Property and equipment, net — 1,432 Operating lease right-of-use asset, net 246,247 454,426 Other Assets: Deposits 38,062 38,062 In-process research and development 92,800,000 59,400,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 68,784,858 Total Assets $ 116,651,751 $ 103,611,150 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 4,927,211 $ 2,927,334 License payable 28,400,000 — Accrued expenses 17,027 476,300 Accrued compensation 2,229,018 2,156,983 Operating lease liability 241,547 218,380 Total Current Liabilities 35,814,803 5,778,997 Deferred tax liability 6,713,800 6,137,800 Operating lease liability – non current 21,318 262,865 Total Liabilities 42,549,921 12,179,662 Commitments and Contingencies Stockholders' Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354 Additional paid-in capital 271,440,421 253,056,133 Accumulated deficit (201,370,218) (162,231,379) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 70,077,450 90,831,108 Non-controlling interest 4,024,380 600,380 Total Equity 74,101,830 91,431,488 Total Liabilities and Equity $ 116,651,751 $ 103,611,150 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 11,906,601 14,819,729 General and administrative 18,249,402 15,295,584 Stock-based compensation – general and administrative 11,839,678 6,616,705 Total Operating Expenses 41,995,681 36,732,018 Operating Loss (41,995,681) (36,732,018) Other Income: Interest income, net 758,000 1,179,417 Gain on sale of New Jersey net operating losses 2,387,842 3,585,689 Total Other Income Net 3,145,842 4,765,106 Loss before Income Taxes (38,849,839) (31,966,912) Income tax expense 576,000 576,000 Net Loss (39,425,839) (32,542,912) Net loss attributable to non-controlling interest 287,000 - Deemed dividend on warrant extension (1,047,312) (1,151,208) Net Loss Applicable to Common Stockholders $ (40,186,151) (33,694,120) Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted $ (5.97) (5.57) Weighted Average Common Shares OutstandingExelixis stock hits 52-week high at $36.6 amid robust growth

6,000 inmates escape from high-security prison as post-election violence roils MozambiqueBroncos elevate DE Matt Henningsen, WR David Sills